Related Experiment Video

Updated: Jun 6, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

A stapled p53 helix overcomes HDMX-mediated suppression of p53

Federico Bernal1, Mark Wade, Marina Godes

  • 1Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.

Cancer Cell
|November 16, 2010
PubMed

Insights

Cancer cells inactivate p53 protein to survive. A new stapled p53 helix drug specifically targets HDMX, reactivating p53 and overcoming cancer resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Cancer cells evade apoptosis by neutralizing the tumor suppressor protein p53 through various mechanisms.
  • Inhibiting the E3 ubiquitin ligase HDM2 can increase p53 levels, but HDMX overexpression can limit this therapeutic effect by sequestering p53.
  • HDMX, an HDM2 homolog, plays a critical role in p53 inactivation in cancer.

Purpose of the Study:

  • To investigate a stapled p53 helix as a novel therapeutic strategy against cancer.
  • To determine if targeting HDMX can overcome HDMX-mediated resistance to p53 reactivation therapies.
  • To provide a framework for personalized cancer therapy by matching inhibitors to specific p53 pathway contexts.

Main Methods:

  • Development and application of a stapled p53 helix peptide.
  • In vitro and in vivo experiments to assess the efficacy of the stapled p53 helix.
  • Analysis of p53-HDMX complex formation and p53 transcriptional activity.
  • Evaluation of cancer cell response to HDM2 and HDMX inhibition.

Main Results:

  • The stapled p53 helix preferentially binds to HDMX.
  • This binding disrupts inhibitory p53-HDMX complexes, preventing p53 sequestration.
  • The treatment leads to p53-dependent transcriptional upregulation and overcomes HDMX-mediated cancer resistance.
  • The study identified specific cellular contexts for HDM2, HDMX, or dual inhibitors.

Conclusions:

  • A stapled p53 helix is a promising therapeutic agent for reactivating the p53 pathway in cancer.
  • Targeting HDMX with this novel agent effectively overcomes cancer resistance mechanisms.
  • Understanding p53 interaction dynamics is crucial for developing effective, context-specific cancer therapies.

More Related Videos

Focus Formation: A Cell-based Assay to Determine the Oncogenic Potential of a Gene08:18

Focus Formation: A Cell-based Assay to Determine the Oncogenic Potential of a Gene

Published on: December 31, 2014

Purification of Ubiquitinated p53 Proteins from Mammalian Cells10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart, a...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.